ICPT - インタ―セプト・ファ―マシュ―ティカルズ (Intercept Pharmaceuticals Inc.)

ICPTのニュース

   Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades  2020/09/02 15:20:00 Barron's
The company was once the front-runner in the race to develop a treatment for NASH, a newly defined liver disease
   Intercept Pharmaceuticals to Reduce Its Workforce by 25%  2020/09/01 18:42:13 The Street
Intercept Pharmaceuticals expects the job cuts to cost about $18 million.
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Why Earnings Season Could Be Great for Intercept (ICPT)  2020/08/07 12:32:12 Yahoo Finance
Intercept (ICPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades  2020/09/02 15:20:00 Barron's
The company was once the front-runner in the race to develop a treatment for NASH, a newly defined liver disease
   Intercept Pharmaceuticals to Reduce Its Workforce by 25%  2020/09/01 18:42:13 The Street
Intercept Pharmaceuticals expects the job cuts to cost about $18 million.
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Why Earnings Season Could Be Great for Intercept (ICPT)  2020/08/07 12:32:12 Yahoo Finance
Intercept (ICPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Who Will Be The Winner In NASH?  2020/07/01 13:21:09 The Street
The same week that Intercept Pharmaceuticals' had its NASH candidate rejected for accelerated…
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm  2020/07/01 01:06:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ICPT #ICPT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc.
   If You Own Intercept Stock, Should You Sell It Now? - Market Realist  2020/06/30 16:05:56 Market Realist
On Monday, Intercept Pharmaceuticals (NASDAQ:ICPT) stock lost 39.7% and closed at $46.70 with a market cap of $1.54 billion.
   Analysts Are Downgrading Intercept Pharmaceuticals. Here’s Why.  2020/06/30 15:53:00 Barron's
Uncertainty over its NASH drug weighs on the stock.
   Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors  2020/06/29 22:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ICPT #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Intercept Pharmaceuticals, Inc. on Behalf of Investors

calendar